Research Topics
Genomes and Genes | Anieta M SieuwertsSummaryAffiliation: Erasmus MC Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancerDanielle Meijer
Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
Endocr Relat Cancer 15:101-11. 2008..In addition, as altered expression of FGF17 causes tamoxifen resistance in vitro, the FGF signaling pathway could be a valuable target in the treatment of breast cancer patients resistant to endocrine treatment...
Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissuesJérôme Toussaint
Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
BMC Genomics 10:424. 2009....- Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancerJack X Yu
Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
BMC Cancer 7:182. 2007..Published prognostic gene signatures in breast cancer have few genes in common. Here we provide a rationale for this observation by studying the prognostic power and the underlying biological pathways of different gene signatures... 
How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective studyAnieta M Sieuwerts
Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
Clin Cancer Res 11:7311-21. 2005..To evaluate the predictive value of the disintegrin and metalloproteinases, ADAM-9, ADAM-10, ADAM-11, and ADAM-12, and of the matrix metalloproteinases, MMP-2 and MMP-9, in patients with recurrent breast cancer treated with tamoxifen...- Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancerAnieta M Sieuwerts
Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
Clin Chem 53:1280-8. 2007..TIMP-1 protein is a prognostic factor for recurrence-free and overall survival (OS) time in breast cancer. We evaluated the prognostic value of TIMP1 mRNA and a novel TIMP1 mRNA splice variant in 1301 primary breast cancer patients... - Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patientsAnieta M Sieuwerts
Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
Clin Cancer Res 12:3319-28. 2006..To evaluate the prognostic value of cyclin E with a quantitative method for lymph node-negative primary breast cancer patients... - Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCRAnieta M Sieuwerts
Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus MC, Room BE 400, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
Breast Cancer Res Treat 118:455-68. 2009..Our method allows molecular characterization specific for as little as one CTC, and can be used to expand the understanding of the biology of metastasis and, potentially, to improve patient management... - Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation studyAnieta M Sieuwerts
Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, GE, The Netherlands
Breast Cancer Res 12:R103. 2010.... - Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cellsAnieta M Sieuwerts
Department of Medical Oncology, Josephine Nefkens Institute, Cancer Genomics Centre, Rotterdam, The Netherlands
J Natl Cancer Inst 101:61-6. 2009..New tests that include antibodies that specifically recognize normal-like breast tumor cells but not cells of hematopoietic origin are needed... - TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancerDanielle Meijer
Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Room Be 432, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
Breast Cancer Res Treat 113:253-60. 2009..Both TSC22D1 and PSAP are associated with clinical outcome and may have a functional role in therapy resistance... - Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancerMaurice P H M Jansen
Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
Breast Cancer Res Treat 116:263-71. 2009..The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in endocrine therapy resistance... - MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancerF Germán Rodríguez-González
Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute and Cancer Genomics Centre, Dr Molewaterplein 50, Be 4 02 lab 4 35b office, PO Box 2040, 3000 CA Rotterdam, The Netherlands
Breast Cancer Res Treat 127:43-51. 2011..Assessment of tumor levels and connected pathways could be helpful to improve treatment strategies... - Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistanceTon van Agthoven
Department of Pathology, Cancer Genomics Center, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
J Clin Oncol 27:542-9. 2009..Here, we explored whether these BCAR genes provide predictive value for tamoxifen resistance and prognostic information for tumor aggressiveness in breast cancer patients... - Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy responseTon van Agthoven
Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Be432, Erasmus MC PO Box 2040, 3000 CA Rotterdam, The Netherlands
Endocr Relat Cancer 17:215-30. 2010.... - HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective studyMaurice P H M Jansen
Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
J Clin Oncol 25:662-8. 2007..However, this ratio may predict a tumor's response to tamoxifen, its intrinsic aggressiveness, or both... - Subtypes of breast cancer show preferential site of relapseMarcel Smid
Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
Cancer Res 68:3108-14. 2008..The five major molecular subtypes in breast cancer are evidently different with regard to their ability to metastasize to distant organ(s), and share biological features and pathways with their preferred distant metastatic site... - mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patientsAnieta M Sieuwerts
Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Rotterdam, The Netherlands
Clin Cancer Res 17:3600-18. 2011..In this study, we determined mRNA and microRNA (miRNA) expression of potentially CTC-specific genes that are considered to be clinically relevant in breast cancer... - Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutationsAntoinette Hollestelle
Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
Breast Cancer Res Treat 122:125-33. 2010..Together, our observations suggest that alpha-catenin may be a new tumor suppressor gene that operates in the E-cadherin tumor suppressor pathway... - Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancerJohn A Foekens
Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute, 3000 CA Rotterdam, The Netherlands
Proc Natl Acad Sci U S A 105:13021-6. 2008..In conclusion, our work connects four miRNAs to breast cancer progression and to several distinct biological processes involved therein... - Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancerJohn W M Martens
Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
Cancer Res 65:4101-17. 2005..Concluding, our work indicates that promoter hypermethylation and mRNA expression of PSAT1 are indicators of response to tamoxifen-based endocrine therapy in steroid hormone receptor-positive patients with recurrent breast cancer... - Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy responseJozien Helleman
Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Clin Cancer Res 14:5555-64. 2008.... - Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genesMuhammad Riaz
Department of Medical Oncology, Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Erasmus MC, Building Be, Room 400, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
Breast Cancer Res Treat 133:843-51. 2012..Also the prognosis of patients is largely not affected by low-risk breast cancer loci except for the SNP near H19. How, this SNP affects prognosis warrants further study as it does not operate through altering H19 mRNA expression... - Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1Buddy Setyono-Han
Department of Medical Oncology, Erasmus Medical Center Rotterdam, 3000 DR Rotterdam, The Netherlands
Thromb Haemost 93:779-86. 2005..In conclusion, our results provide evidence that WX-UK1 as a single agent inhibits breast tumour growth and metastasis in vivo, and thus is a promising candidate drug to treat human cancer... - Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progressionJohn W M Martens
Dept of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
Thromb Haemost 89:393-404. 2003..These age-induced levels of PAI-1, FGF-1, uPA and MMP-2 in stromal breast fibroblast could contribute to breast cancer progression... - CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypesBianca Mostert
Erasmus MC, Department of Medical Oncology, Daniel den Hoed Cancer Center and Laboratory of Translational Tumor Immunology, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Cancer Lett 319:49-55. 2012..Combined staining of CK8/18/19 and CD49f after CD146/EpCAM enrichment is likely to further improve CTC detection in breast cancer... - Genes associated with breast cancer metastatic to boneMarcel Smid
Department of Medical Oncology, Erasmus MC-Daniel den Hoed, Rotterdam, The Netherlands
J Clin Oncol 24:2261-7. 2006.... - Hormone replacement therapy dependent changes in breast cancer-related gene expression in breast tissue of healthy postmenopausal womenAnieta M Sieuwerts
Department of Medical Oncology, Josephine Nefkens Institute, Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, Netherlands
Mol Oncol 5:504-16. 2011..This feasibility study provides the basis for whole genome analyses to identify novel markers involved in increased breast cancer risk... - Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146Bianca Mostert
Department of Medical Oncology, Daniel den Hoed Cancer Center and Laboratory of Translational Tumor Immunology, Erasmus MC, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Breast Cancer Res Treat 127:33-41. 2011..CD146+ CTCs are present in the peripheral blood of breast cancer patients with advanced disease. Combined use of anti-CD146 and anti-EpCAM is likely to improve CTC detection in breast cancer patients... - Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profilingMaurice P H M Jansen
Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
J Clin Oncol 23:732-40. 2005..Additional studies are needed to confirm if the predictive signature might allow identification of individual patients who could benefit from other (adjuvant) endocrine therapies... - Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypesJord H A Nagel
Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands
Breast Cancer Res Treat 132:439-48. 2012..Identification of these as-yet-unknown susceptibility alleles should be aided by clues from the 40-gene CHEK2 signature... - Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancerJohn A Foekens
Department of Medical Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
J Clin Oncol 24:1665-71. 2006..The aim of this study was to validate this gene signature in an independent more diverse population of LNN patients from multiple institutions... - Circulating tumour cell detection on its way to routine diagnostic implementation?Stefan Sleijfer
Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Clinic, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Eur J Cancer 43:2645-50. 2007..This review addresses CTCs, and in particular, technical issues concerning their detection, clinical results obtained so far, and future perspectives... - Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypesMarcel Smid
Department of Medical Oncology, Josephine Nefkens Institute, Erasmus MC, Dr, Rotterdam, The Netherlands
Breast Cancer Res Treat 128:23-30. 2011..In contrast, CIN is clearly associated with progression in ER-positive, luminal B, and her2/neu subtypes; thus, assessing CIN in these subtypes may contribute to personalized patient management... - KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissueBianca Mostert
Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Int J Cancer 133:130-41. 2013..Determination of KRAS and BRAF mutations in CTCs is challenging but feasible. Of the tested methods, nested ASB-PCR, enabling detection of KRAS and BRAF mutations in patients with as little as two CTCs, seems to be superior... - Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancerAntoinette Hollestelle
Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Breast Cancer Res Treat 138:47-57. 2013..The discrepancy between E-cadherin loss and EMT was thus reproduced in clinical samples. Together, these results indicate that in human breast cancer loss of E-cadherin is not causal for EMT and even not a necessity... - Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patientsBianca Mostert
Daniel den Hoed Cancer Center, Laboratory of Clinical Tumor Immunology, Rotterdam, The Netherlands
Expert Rev Mol Diagn 11:259-75. 2011.... - Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblastsAnieta M Sieuwerts
Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
Thromb Haemost 87:674-83. 2002.... - Differential expression of splicing variants of the human caldesmon gene (CALD1) in glioma neovascularization versus normal brain microvasculaturePing Pin Zheng
Department of Pathology, Internal Oncology, Neuro Oncology and Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
Am J Pathol 164:2217-28. 2004..The event coexists with tight junction (TJ) breakdown of the endothelial cells in glioma microvasculature. The data reveal a novel mechanism contributing to dysfunctionality of glioma neovascularization... - The challenge of gene expression profiling in heterogeneous clinical samplesF Germán Rodríguez-González
Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, The Netherlands
Methods 59:47-58. 2013.... - Multiplex molecular analysis of CTCsAnieta M Sieuwerts
Department of Translational Cancer Genomics and Proteomics, Erasmus Medical Center, Rotterdam, The Netherlands
Recent Results Cancer Res 195:125-40. 2012..However, most of what is discussed will apply to any multiplex analysis of CTCs, irrespective of the enrichment method... - Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factorMatthias Kotzsch
Institute of Pathology, Dresden University of Technology, Fetscherstr 74, 01307, Dresden, Germany
Breast Cancer Res Treat 111:229-40. 2008..To evaluate the pure prognostic impact of the uPA-receptor splice variant uPAR-del4/5 for lymph node-negative breast cancer patients, and to identify differentially expressed genes associated with high or low uPAR-del4/5 mRNA levels... - Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancerYixin Wang
Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
Lancet 365:671-9. 2005..The ability to identify patients who have a favourable prognosis could, after independent confirmation, allow clinicians to avoid adjuvant systemic therapy or to choose less aggressive therapeutic options... - DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patientsInko Nimmrich
Department of Biomedical Research and Development and Technology Development, Epigenomics AG, Berlin, Germany
Breast Cancer Res Treat 111:429-37. 2008..In addition, we studied the association between PITX2 DNA methylation and PITX2 gene expression... - Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancerSelina Raguz
Medical Research Council Clinical Sciences Centre, Imperial College Faculty of Medicine, Hammersmith Hospital Campus, London, United Kingdom
Int J Cancer 122:1058-67. 2008....